Rocatinlimab showed significant improvement in eczema symptoms compared to placebo after 16 weeks of treatment. The benefits continued even after stopping treatment, suggesting a potential long-lasting effect.
-
Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis
Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis
Shivali Devjani, Priya V Engel, Sogol S Javadi, Brandon Smith, Jashin J Wu
DOI: 10.1016/S0140-6736(23)01619-7
Comment
•
274 participants
•
2023
•
0 citations
-
What is this paper about?
-
What populations did the authors study?
274 patients. With moderate to severe eczema. Patients are 18-75 years.
-
What did the authors find?
Analyzing metric: EASI-75.
Findings show: Invervention leads to 57.4% (600mg Q2W).
Resulting in: More than half of patients on the highest dose achieved 75% improvement in their eczema symptoms compared to only 15% on placebo.
Analyzing metric: IGA.
Findings show: Invervention leads to 45.9% (600mg Q2W).
Resulting in: Nearly half of patients on the highest dose achieved clear or almost clear skin compared to 13% on placebo. -
What conclusions can we draw?
nan
